LONG FACTOR CERTIFICATE - UCB Stock

ZJ5IH

DE000GP4F445

Market Closed - Euronext Paris 12:30:01 2024-06-07 EDT
8.5 ^EUR	+3.16%

Current month	+15.40%
1 month	+76.09%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB : Acquisition of own shares	05-31	PU
UCB : Commitment to Innovation in Drug Development	05-29	PU
UCB : announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa	05-23	PU
UCB - Acquisition of own shares	05-20	AQ

More news

Quotes 5-day view

Date	Price	Change
24-06-07	8.47	+2.79%
24-06-06	8.24	+0.61%
24-06-05	8.19	+16.17%
24-06-04	7.05	+4.60%
24-06-03	6.74	-8.17%

Real-time Euronext Paris

Last update June 07, 2024 at 12:30 pm

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	UCB
Issuer	Goldman Sachs
	ZJ5IH
ISIN	DE000GP4F445
Date issued	2023-05-08
Strike	119.1 €
Maturity	Unlimited
Parity	1.34 : 1
Emission price	10 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	21.91 €
Lowest since issue	0.04 €
Spread	0.3 €
Spread %	3.48%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

130 EUR

Average target price

126.4 EUR

Spread / Average Target

-2.78%

Consensus